Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11948857 | 0.87 | PRCP (0.55) | PRCPGAAGID4RECQLMAOA | |
| SCHEMBL11948841 | 0.85 | PRCP (0.47) | PRCPGAAGID4RECQLMAOA | |
| SCHEMBL11948844 | 0.84 | PRCP (0.46) | PRCPGAAGID4RECQLMAOA | |
| SCHEMBL11948846 | 0.83 | GID4 (0.57) | PRCPGAAGID4RECQLMAOA | |
| SCHEMBL4120535 | 0.83 | PRCP (0.50) | PRCPGAAGID4RECQLMAPT | |
| SCHEMBL11948845 | 0.82 | GID4 (0.56) | PRCPGAAGID4RECQLMAOA | |
| SCHEMBL11948843 | 0.79 | OPRM1 (0.44) | PRCPGAAGID4MAOAMAPT | |
| SCHEMBL11948855 | 0.79 | PRCP (0.48) | PRCPGAAGID4RECQLMAOA | |
| SCHEMBL2676256 | 0.79 | PRCP (0.59) | PRCPGAAGID4RECQLMAPT | |
| SCHEMBL4399590 | 0.78 | GAA (0.54) | PRCPGAAGID4RECQLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232399-B2 | Chiral ligands, their preparation and uses thereof in asymmetric reactions | Li, Chao-Jun (CA) | 2012-07-31 | — | — | US | disclosed |
| US-8183378-B2 | Ligands, their preparation and uses thereof in asymmetric reactions | Li, Chao-Jun (CA) | 2012-05-22 | — | — | US | disclosed |
| US-20090247757-A1 | LIGANDS, THEIR PREPARATION AND USES THEREOF IN ASYMMETRIC REACTIONS | CHAO-JUN LI (CA) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247757-A1 | LIGANDS, THEIR PREPARATION AND USES THEREOF IN ASYMMETRIC REACTIONS | OGFR, OR10J3, OPRL1 | PRCP 3913/4885GAA 4883/4885GID4 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.